- Company
- 'Vonjo' for myelofibrosis expected to be marketed in KOR
- by Eo, Yun-Ho Jun 5, 2025 06:11am
- The oral myelofibrosis treatment 'Vonjo' is expected to be commercialized in Korea. According to industry sources, the Ministry of Food and Drug Safety is conducting an approval review of Vonjo (pacritinib). This drug obtained orphan drug designation (ODD) in September of last year. Vonjo is indicated for 'treatment of intermediate-ri
- Policy
- Lee 'will strengthen public nature of medical sector'
- by Lee, Jeong-Hwan Jun 5, 2025 06:10am
- With the election of President Lee Jae-Myung, the legal community predicts that the government will strengthen its public policy in the healthcare and pharmaceutical biotechnology sectors. The areas of AI-based digital healthcare industry, rare and intractable disease coverage, and regional essential medical infrastructure will see new op
- Company
- Global pharmas race to introduce bispecific antibodies
- by Son, Hyung Min Jun 5, 2025 06:10am
- Major global pharmaceutical companies are challenging the throne held by the immunotherapy Keytruda with their respective bispecific antibodies. Recently, BMS signed a partnership agreement with Germany's BioNTech to develop a new bispecific antibody, while Pfizer successfully introduced a bispecific antibody from China's 3SBio last month. MSD a
- Policy
- Lee Jae-Myung elected as president of South Korea
- by Lee, Jeong-Hwan Jun 5, 2025 06:10am
- With the election of Lee Jae-myung of the Democratic Party (Candidate No. 1) as the 21st President of South Korea, momentum is expected to build for key healthcare policies. These include the establishment of a National Medical Reform Public Opinion Committee to resolve conflicts between the medical community and the government, the promotion
- Company
- "Effect of Camzyos confirmed in Korean patients with oHCM"
- by Son, Hyung Min Jun 5, 2025 06:09am
- "After Camzyos was introduced to Korea, patients with obstructive hypertrophic cardiomyopathy (oHCM) and doctors have high treatment satisfaction. Notably, realworld data showed that Camzyos administration had a comparable effect to confirmatory clinical trial." During a recent meeting with Daily Pharm, Hyung-Kwan Kim, Professor of Seoul
- Company
- K-Bios eye US’s reintroduction of the Biosecure Act
- by Cha, Jihyun Jun 4, 2025 06:21am
- The U.S. is pushing ahead with its Biosecure Act that restricts transactions with Chinese biotech companies. According to the Korea Biotechnology Industry Organization (KoreaBIO) on the 2nd, U.S. Democrat Senator Gary Peters recently announced at a Brookings Institution event that he would soon reintroduce the Biosecure Act, which restri
- Company
- More treatment options for PNH…entry of 'Piasky' imminent
- by Eo, Yun-Ho Jun 4, 2025 06:19am
- The entry 'Piasky,' a new PNH drug, into the Korean market is imminent. According to industry sources, Roche Korea's Piasky (crovalimab), a treatment for paroxysmal nocturnal hemoglobinuria (PNH), is undergoing final review for approval by the Ministry of Food and Drug Safety (MFDS). It is expected to be officially approved in the second
- Policy
- Premium pricing for 11 linagliptin products ends on the 9th
- by Lee, Tak-Sun Jun 4, 2025 06:19am
- As one year has passed since the entry of generic versions of the DPP-4 inhibitor diabetes treatment Trajenta (linagliptin), the price ceiling of 11 products that received pricing premiums will be adjusted on the 9th. Three products that entered the market in March following the expiration of the first generic exclusivity period will also
- InterView
- "Livtencity offers new CMV trt for transplant patients"
- by Whang, byung-woo Jun 4, 2025 06:19am
- "Cytomegalovirus (CMV) infection is worse than a simple viral infection in patients with solid organ transplant (SOT), but existing treatments have limitations. Reimbursement of new medicines is meaningful in terms of extending treatment options." Livtencity (maribavir), which can be prescribed to post-transplant patients who have had limited
- Company
- UCB Korea launches psoriasis drug Bimzelx with reimb
- by Whang, byung-woo Jun 4, 2025 06:18am
- On June 2, UCB Korea (CEO Sujin Hwang) announced that its psoriasis treatment Bimzelx (bimekizumab) was launched on June 1 with reimbursement coverage under the national health insurance system. In line with the Ministry of Health and Welfare (MOHW) notification, Bimzelx is reimbursed as a treatment for moderate-to-severe plaque psoriasis
